Millennium Management LLC purchased 778 shares of Sensei Biotherapeutics for $21,182, signaling confidence in the company's strategic pivot to its oral therapy PIKTOR. This rare reversal trade comes as the stock has dropped 23.78% over the last 30 days despite a massive 125.14% gain over the last 90 days.
Price context
The stock is currently trading at $20.465, down 23.78% over the last 30 days but still up 125.14% over the last 90 days, leaving it 44.33% below its 52-week high of $36.76.
Catalysts to watch
Analysts highlighted Sensei as a top NASDAQ performer on May 5, 2026, following the acquisition of Faeth Therapeutics and the pivot to the oral therapy PIKTOR. Additionally, the company is currently executing a strategic review to maximize shareholder value following the decision to drop its lead candidate.
Risks
The company cut its workforce and dropped its lead candidate in a strategic review on October 31, 2025, raising questions about the viability of its clinical pipeline. With a market cap of approximately $22 million, the stock is highly susceptible to liquidity issues and volatility.
AI-generated context from public data. Not investment advice. Verify before trading.